Furthermore, inhibition of aspirin-triggered specialized proresolving mediator (AT-SPM) biosynthesis or knockout of the AT-SPM receptor Alx/Fpr2 counteracted the immunomodulatory effects and diminished the protective impact of aspirin against CRC [48]. Here, FPR2 is linked to colorectal carcinoma.